A patient is sitting at their kitchen table. Alone. With a pre-filled syringe and a 40-page leaflet. This is the moment a self-administration video has to work — not the moment it's filmed, not the moment it's approved by MLR, but the moment a real person has to inject themselves correctly on the first try.
Most self-admin videos miss this. They're shot like a product demo: clean hands, clinical voiceover, steps rushed in 90 seconds. That format suits a sales conference. It does not suit a frightened patient at 11pm.
Research published in Pharmaceutical Commerce notes that fear and anxiety around self-administration drive avoidance behaviours, and that consistent multi-touchpoint patient education is needed to reduce errors, particularly early in treatment when mistakes are most severe. A well-made video is one of those touchpoints. A badly made one is wasted budget.
How to produce a self-administration video for a biologic
The first decision is positioning. A self-injection training video is non-promotional patient-facing content, regulated and reviewed differently from a brand asset. Promedia's work on UCB's BIMZELX self-injection instruction videos, produced in BE/FR, BE/NL and CH/DE, makes this explicit: every version opens with a mandatory disclaimer stating that the video derives from the Patient Information Leaflet, does not replace it, and must not be used by patients who have not first been trained by a healthcare professional. Adverse-event reporting pathways, including UCBCares and local pharmacovigilance portals, are embedded from the first screen.
That framing changes the entire production. Scripts are versioned, country-adapted, and submitted through the MLR/ACC review cycle. The video is locked in English first, then localised — never the other way around.
This also means the video does not live alone. In the UCB TK2d global patient-facing materials plan, the administration video is listed alongside the Getting Started Guide, Medication Dosing Card, and Administration Mat as a mandatory ACC R1 review item. Self-admin video sits inside a structured content pipeline, not as a standalone marketing asset.
What should a pharma self-injection video include
There are five elements that separate a clinical tool from a glossy demo.
- A patient-point-of-view script. "You will feel a small resistance" beats "the plunger activates the mechanism." A 2013 study indexed in PubMed showed that plain-language patient instructions for use measurably improved understanding and the demonstrated correctness of self-administration steps with a biologic auto-injector, compared with standard instructions.
- Real pacing on critical steps. The injection site selection, the angle of the device, the hold time. These are where errors happen. Give them screen time, even if it breaks the 90-second instinct.
- Mistakes shown, not hidden. What does it look like when the needle is not fully inserted? When the device is lifted too early? Patients remember the wrong version as much as the right one. Showing the error pattern is more protective than hoping they read the warnings.
- Subtitles on every frame. Many patients watch in silence at night, next to a sleeping partner. No subtitle means no information.
- A clear next step. Where to call. Who to ask. What to do if something feels wrong. This is not optional in a market that takes pharmacovigilance seriously.
These are not stylistic preferences. They are the difference between a video that supports adherence and one that creates support-line volume.
How do you align a self-admin video with the PIL and SmPC
Word-for-word. Dosing, handling, storage, contraindications, adverse-event language: all of it has to match the approved Summary of Product Characteristics and Patient Information Leaflet. MLR will check. Brand teams should check before filming, because reshoots cost more than rewrites.
Promedia's published guidance on the MLR review cycle is direct on this: the cycle itself is not the bottleneck. Everything that happens before submission is. The agencies that move fastest co-create with medical, legal and regulatory at the brief stage, build a modular repository of pre-approved claims, lock the global English master before localisation begins, and pre-mark every source inside the document before submission. A generalist production house unfamiliar with SmPC and PIL conventions will produce a script that gets flagged at every review stage, costing weeks of rework. The savings on the day rate disappear inside the first review cycle.
The practical workflow: pull the dosing and handling language directly from the PIL into the script. Have medical review the storyboard, not just the final cut. Submit the English master through MLR/ACC before any localisation kicks off. Then, and only then, version for each market.
How do you make a self-injection video accessible to patients
Accessibility is not a finishing touch. It is a design constraint from the first storyboard.
Subtitles in every language version, including the source. Closed captions, not burned-in, where the hosting platform supports them. Clear high-contrast on-screen text for device names, dosages and warnings. Voiceover paced for non-native speakers, because the country of approval is rarely the only country where the patient learned the language. Audio description tracks where the visual content carries clinical meaning that the voiceover does not repeat.
This matters because adherence is fragile. Promedia's internal data, cited alongside AbbVie in patient-engagement presentations, shows that up to 50% of patients globally do not adhere to their prescribed treatment, and that unengaged patients are up to three times more likely to delay care, have unmet medical needs, or drop out entirely. Older research published in PMC found that for persons with chronic disorders, as many as 60% may be poorly adherent, with patient-training resources identified as a key driver of persistence with self-injectable therapies. The self-admin video is one of the few content assets that directly touches this lever.
